Specialty pipeline deals advanced on two fronts this week, with companies in both nephrology and sleep medicine signing new licensing and collaboration agreements to push clinical-stage assets toward patients.

CSL and Alentis Therapeutics ink global collaboration for lixudebart

CSL and Alentis Therapeutics have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart. Under terms of the agreement, CSL is expected to make an initial payment of $355 million to Alentis, with the company also being eligible to receive upwards of an additional $1.2 billion in commercial milestone payments.¹ As part of the deal, CSL will fully fund completion of the ongoing Phase II Renal trial and a planned Phase III trial in AAV-RPGN, along with Phase II trials in FSGS and PSC and other supporting development activities.¹

Once commercialized, global profits are planned to be shared 55% to CSL and 45% to Alentis.¹

Lixudebart holds the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases, as it is currently being evaluated in the ongoing Phase II Renal trial in patients with ANCA-associated vasculitis with rapidly progressive glomerulonephritis, a rare and potentially life-threatening autoimmune disease that can cause irreversible kidney damage and end-stage renal disease.¹

With a novel mechanism of action, lixudebart exerts potent anti-inflammatory and anti-fibrotic effects intended to prevent and reverse organ damage in AAV and numerous other kidney, liver and lung diseases, and the ongoing Phase II trial is designed to translate those mechanistic effects into meaningful clinical impact.¹

"This partnership enables us to dramatically accelerate the development of lixudebart in several indications in parallel," said Dr Mark Pruzanski, chief executive officer of Alentis Therapeutics. "We are convinced CSL's demonstrated clinical development and commercialisation capabilities in AAV and kidney diseases makes them the right partner to bring lixudebart to patients. More broadly, this furthers the validation of claudin-1 as a novel therapeutic target and we are excited about the potential to accelerate the advancement of our other clinical stage assets and preclinical pipeline."

Jiangsu Nhwa licenses sleep disorder candidate to Somnivera

Jiangsu Nhwa Pharmaceutical Co., Ltd. enters an exclusive licensing agreement with Somnivera, Inc., a U.S. biotechnology company, for an investigational clinical-stage drug candidate targeting sleep disorders.

Under terms of the agreement, Nhwa is set to receive an upfront payment of $10.5 million and is eligible for up to $507 million in additional milestone payments, along with tiered royalties in the single-digit to low double-digit percentage range on net sales and a share of sub-licensing income.² Nhwa is also acquiring a 15% equity stake in Somnivera through its wholly-owned subsidiary, Nhwa Pharma (Hong Kong) Limited.²

As part of the deal, Somnivera is granted exclusive rights to develop, manufacture, and commercialize the asset worldwide, excluding Mainland China, Hong Kong SAR, Macao SAR and the Taiwan region, where Nhwa retains commercial rights.² The candidate addresses sleep disorders, a CNS indication with high global prevalence and substantial unmet need beyond currently marketed hypnotics.² The asset is currently in the clinical stage of development, with the specific phase, target, mechanism of action, and trial data not being disclosed.²

Sources

1. CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases CSL October 4, 2026, https://www.prnewswire.com/news-releases/csl-and-alentis-announce-global-partnership-to-develop-and-commercialise-lixudebart-for-rare-kidney-and-liver-diseases-302897821.html
2. Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value FineLine September 30, 2026, https://flcube.com/jiangsu-nhwa-signs-exclusive-global-licensing-deal-with-somnivera-clinical-stage-sleep-disorder-asset-backed-by-up-to-us517-5-million-in-potential-value/#google_vignette